Cargando…
Anti-HER2/Neu passive-aggressive immunotherapy
Preclinical studies have established that CD8(+) T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, best known as HER2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER2/Neu the...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935925/ https://www.ncbi.nlm.nih.gov/pubmed/24605268 http://dx.doi.org/10.4161/onci.27296 |